Australia’s CSL in exclusive talks for $7 bln buyout of Swiss Vifor Pharma
Australian biopharmaceutical giant CSL Ltd (CSL.AX) is in exclusive talks to buy Swiss drugmaker Vifor Pharma (VIFN.S) in a A$10 billion ($7 billion) deal, Australian media reported, sending the Swiss
Read More